Hippocampal and neocortical BRAF mutant non-expansive lesions in focal epilepsies

Julie Lerond1, Bertrand Mathon2, Mélina Scopin3

  • 1Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Sorbonne Université, Paris, France.

PubMed
Abstract

Insights

The BRAFV600E oncogenic variant was identified in a subset of Mesial Temporal Lobe Epilepsy-associated Hippocampal Sclerosis (MTLE-HS) and neocortical lesions. This discovery may aid in diagnosing MTLE-HS and developing targeted therapies for epilepsy.

Area of Science:

  • Neuroscience
  • Oncology
  • Genetics

Background:

  • Mesial Temporal Lobe Epilepsy-associated Hippocampal Sclerosis (MTLE-HS) is a complex neurological syndrome with diverse underlying causes.
  • Previous research suggested a potential link between CD34-positive extravascular stellate cells (CD34+ cells) and the BRAFV600E oncogenic variant in a subset of MTLE-HS cases.

Purpose of the Study:

  • To identify the presence and prevalence of the BRAFV600E oncogenic variant in MTLE-HS and related lesions.
  • To characterize the nature and cellular origins of CD34+ cells in these conditions.

Main Methods:

  • BRAFV600E variant analysis using digital droplet Polymerase Chain Reaction in MTLE-HS and neocortical lesion samples.
  • Ex vivo multi-electrode array recording, immunolabelling, methylation microarray, and single nuclei RNA sequencing were employed.

Main Results:

  • The BRAFV600E variant was detected in 19% of MTLE-HS samples with CD34+ cells and 100% of neocortical samples with CD34+ cells.
  • Single nuclei RNA sequencing revealed unique cell clusters associated with senescence and oligodendrocyte development in BRAFV600E mutant samples.
  • CD34+ cells expressed p16INK4A and HOPX, indicating a progenitor-to-myelinating oligodendrocyte lineage.

Conclusions:

  • The BRAFV600E oncogenic variant is implicated in a subset of MTLE-HS and epileptogenic neocortical focal lesions.
  • Identifying this variant could improve diagnostic accuracy for these conditions.
  • The findings open avenues for developing targeted therapeutic strategies for BRAFV600E-driven epilepsy.